Compare · ALVO vs SGEN
ALVO vs SGEN
Side-by-side comparison of Alvotech (ALVO) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALVO and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 21.6x ALVO ($1.08B).
- ALVO has hit the wire 2 times in the past 4 weeks while SGEN has been quiet.
- SGEN has more recent analyst coverage (25 ratings vs 10 for ALVO).
- Company
- Alvotech
- Seagen Inc.
- Price
- $3.45+2.22%
- $228.86-0.01%
- Market cap
- $1.08B
- $23.34B
- 1M return
- -10.62%
- -
- 1Y return
- -60.05%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2001
- News (4w)
- 2
- 0
- Recent ratings
- 10
- 25
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest ALVO
- SEC Form 6-K filed by Alvotech
- Alvotech further strengthens liquidity by securing term loan facility of $75 million
- SEC Form 6-K filed by Alvotech
- Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
- SEC Form 6-K filed by Alvotech
- SEC Form 424B5 filed by Alvotech
- SEC Form FWP filed by Alvotech
- Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
- SEC Form FWP filed by Alvotech
- SEC Form 424B5 filed by Alvotech
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)